全文获取类型
收费全文 | 3287篇 |
免费 | 268篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 16篇 |
儿科学 | 68篇 |
妇产科学 | 92篇 |
基础医学 | 573篇 |
口腔科学 | 22篇 |
临床医学 | 228篇 |
内科学 | 712篇 |
皮肤病学 | 47篇 |
神经病学 | 352篇 |
特种医学 | 131篇 |
外科学 | 453篇 |
综合类 | 15篇 |
一般理论 | 2篇 |
预防医学 | 254篇 |
眼科学 | 24篇 |
药学 | 301篇 |
中国医学 | 5篇 |
肿瘤学 | 264篇 |
出版年
2023年 | 24篇 |
2022年 | 37篇 |
2021年 | 76篇 |
2020年 | 48篇 |
2019年 | 52篇 |
2018年 | 84篇 |
2017年 | 50篇 |
2016年 | 59篇 |
2015年 | 71篇 |
2014年 | 92篇 |
2013年 | 130篇 |
2012年 | 162篇 |
2011年 | 125篇 |
2010年 | 69篇 |
2009年 | 74篇 |
2008年 | 131篇 |
2007年 | 139篇 |
2006年 | 137篇 |
2005年 | 118篇 |
2004年 | 136篇 |
2003年 | 127篇 |
2002年 | 131篇 |
2001年 | 98篇 |
2000年 | 109篇 |
1999年 | 119篇 |
1998年 | 45篇 |
1997年 | 28篇 |
1996年 | 39篇 |
1995年 | 35篇 |
1994年 | 31篇 |
1993年 | 22篇 |
1992年 | 101篇 |
1991年 | 87篇 |
1990年 | 70篇 |
1989年 | 81篇 |
1988年 | 70篇 |
1987年 | 60篇 |
1986年 | 61篇 |
1985年 | 64篇 |
1984年 | 32篇 |
1983年 | 30篇 |
1982年 | 18篇 |
1981年 | 20篇 |
1979年 | 29篇 |
1977年 | 31篇 |
1976年 | 23篇 |
1975年 | 22篇 |
1973年 | 27篇 |
1972年 | 20篇 |
1969年 | 18篇 |
排序方式: 共有3559条查询结果,搜索用时 15 毫秒
81.
82.
Emilie Ronin Charlotte Pouchy Maryam Khosravi Morgane Hilaire Sylvie Grgoire Armanda Casrouge Sahar Kassem David Sleurs Gaëlle H. Martin Nomie Chanson Yannis Lombardi Guilhem Lalle Harald Wajant Cdric Auffray Bruno Lucas Gilles Marodon Yenkel Grinberg-Bleyer Benoît L. Salomon 《Proceedings of the National Academy of Sciences of the United States of America》2021,118(13)
83.
84.
85.
Advance directives (ADs) have been hailed for two decades as the best way to safeguard patients’ autonomy when they are totally or partially incompetent. In many national contexts they are written into law and they are mostly associated with end-of-life decisions. Although advocates and critics of ADs exchange relevant empirical and theoretical arguments, the debate is inconclusive. We argue that this is so for good reasons: the ADs’ project is fraught with tensions, and this is the reason why they are both important and deeply problematic. We outline six such tensions, and conclude with some positive suggestions about how to better promote patients’ autonomy in end-of-life decision. We argue that ADs should continue to be an option but they cannot be the panacea that they are expected to be. 相似文献
86.
B. Lassale M. Fournier I. Dettori J.-P. Aullen 《Transfusion Clinique et Biologique》2012,19(4-5):202-205
Transfusions are exceptional while patients are rushed to hospital for sanitary reasons. The quality of care requires the collaboration with different partners (samu, blood bank centre, haemovigilance correspondents…). In response to dysfunctions that occurred during transports for sanitary reasons we have drawn up a regional procedure, which specifies how to get and use blood products. This procedure harmonizes our medical practice, states the role of the different participants (traceability of blood samples of immunohaematology tests, etc.), including a part dedicated to identity vigilance. The expected impacts of this procedure are: the decrease of dysfunctions and of destructions of red blood cells, the improvement of security while patients are transfused. 相似文献
87.
88.
89.
Diagnosing Staphylococcus aureus endocarditis by detecting antibodies against S. aureus capsular polysaccharide types 5 and 8 总被引:4,自引:0,他引:4
B Christensson A Boutonnier U Ryding J M Fournier 《The Journal of infectious diseases》1991,163(3):530-533
Consecutive serum samples from patients with Staphylococcus aureus endocarditis or septicemia or non-S. aureus endocarditis and febrile nonsepticemic controls were tested for antibodies against S. aureus capsular polysaccharide (CP) types 5 and 8 by ELISA. The upper normal antibody levels were defined as the upper 99.5% confidence limits of the values from the febrile controls. All available patient isolates were tested for the presence of CP type 5 or 8 (85% of the isolates expressed either serotype), and all five patients with S. aureus endocarditis had positive antibody levels against the corresponding serotype within the first 10 days of infection. Three other endocarditis patients lacked isolates for CP testing but two of these were positive. Positive antibody levels were found in 0 of 28 septicemia patients, in 1 of 12 non-S. aureus endocarditis patients, and in 3 of 37 febrile controls. Thus, testing for anti-CP 5 or 8 antibodies, especially together with CP serotyping of the patient's isolate, seems to provide important information in the differential diagnosis of endocarditis in patients with S. aureus septicemia. 相似文献
90.
Outcome and treatment of Bartonella endocarditis 总被引:5,自引:0,他引:5
Raoult D Fournier PE Vandenesch F Mainardi JL Eykyn SJ Nash J James E Benoit-Lemercier C Marrie TJ 《Archives of internal medicine》2003,163(2):226-230
BACKGROUND: Endocarditis caused by Bartonella species is a potentially lethal infection characterized by a subacute evolution and severe valvular lesions. OBJECTIVES: To evaluate the outcome of patients with Bartonella endocarditis and to define the best antibiotic regimen using the following measures: recovery, relapse, or death. METHODS: We performed a retrospective study on 101 patients who were diagnosed in our laboratory as having Bartonella endocarditis between January 1, 1995, and April 30, 2001. Bartonella infection was diagnosed using immunofluorescence with a 1:800 cutoff, polymerase chain reaction amplification of DNA, and/or culture findings of Bartonella species from whole blood, serum, and/or valvular biopsy specimens. A standardized questionnaire was completed by investigators for each patient. RESULTS: Twelve of the 101 patients died and 2 relapsed. Patients receiving an aminoglycoside were more likely to fully recover (P =.02), and those treated with aminoglycosides for at least 14 days were more likely to survive than those with shorter therapy duration (P =.02). CONCLUSION: Effective antibiotic therapy for Bartonella endocarditis should include an aminoglycoside prescribed for a minimum of 2 weeks. 相似文献